Atea Pharmaceuticals (ATEA) Reports Q4 Revenue Up 15% to $285M

Atea Pharmaceuticals (ATEA) released Q4 2025 results showing revenue of $285 million, a 15% increase from $248 million in the same period of 2024. Gross profit rose to $200 million from $178 million, and the company reported a net loss of ($35 million) compared to a ($28 million) loss in Q4 2024, reflecting higher R&D spending. The improvement followed strong sales of its top-selling rheumatoid arthritis therapy, Ategalny, which contributed 65% of total revenue in the quarter. The company raised its full-year 2025 revenue guidance to $1.1 billion from $1.05 billion, citing continued outperformance of key products.